-Matthew M Ames Researcher Activity Profile

Research Author Detailed Information 

Matthew M Ames Publication Rate By Year

Matthew M Ames has published 1 paper(s) in 2006, 16 paper(s) in 2007, 1 paper(s) in 2008, for a total of 18 research publications in total.

Matthew M Mm Ames Author Information

LAST NAME: ames

FIRST NAME: Matthew M

INITIALS: mm

AFFILIATION:

Papers

Matthew M Ames's Publication Record

1. Phase I trial and pharmacokinetic study of pemetrexed in children with refractory solid tumors: the Children's Oncology Group. Year Published: 2007
Department of Pediatrics, Oregon Health & Science University, Portland, OR 97239-3098, USA. malempat@ohsu.edu
2. Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics. Year Published: 2006
Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA.
3. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Year Published: 2007
Department of Oncology, Mayo Clinic College of Medicine, 200 First Street Southwest, Rochester, MN , 55905, USA, goetz.matthew@mayo.edu.
4. Inhibition of mitochondrial respiration as a source of adaphostin-induced reactive oxygen species and cytotoxicity. Year Published: 2007
Department of Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA.
5. Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/leucovorin for metastatic colorectal cancer. Year Published: 2007
Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN 55905, USA. mcwilliams.robert@mayo.edu
6. Identification and characterization of genetic variation in the folylpolyglutamate synthase gene. Year Published: 2007
Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA.
7. A limited sample model to predict area under the drug concentration curve for 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite 17-(amino)-17-demethoxygeldanomycin. Year Published: 2007
Division of Biostatistics, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA.
8. Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide. Year Published: 2007
Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
9. Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide. Year Published: 2007
Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
10. Toxicology and pharmacokinetics of 1-methyl-d-tryptophan: Absence of toxicity due to saturating absorption. Year Published: 2007
Developmental Therapeutics Program, National Cancer Institute, Rm 8042, 6130 Executive Blvd., Bethesda, MD 20852, United States.
11. Phase I trial and pharmacokinetic study of pemetrexed in children with refractory solid tumors: the Children's Oncology Group. Year Published: 2007
Department of Pediatrics, Oregon Health & Science University, Portland, OR 97239-3098, USA. malempat@ohsu.edu
12. Tamoxifen Pharmacogenomics: The Role of CYP2D6 as a Predictor of Drug Response. Year Published: 2007
1Department of Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.
13. A limited sample model to predict area under the drug concentration curve for 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite 17-(amino)-17-demethoxygeldanomycin. Year Published: 2007
Division of Biostatistics, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA.
14. Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response. Year Published: 2007
Department of Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA. goetz.matthew@mayo.edu
15. Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response. Year Published: 2007
Department of Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA. goetz.matthew@mayo.edu
16. Identification and characterization of genetic variation in the folylpolyglutamate synthase gene. Year Published: 2007
Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA.
17. Toxicology and pharmacokinetics of 1-methyl-d-tryptophan: absence of toxicity due to saturating absorption. Year Published: 2007
Developmental Therapeutics Program, National Cancer Institute, Rm 8042, 6130 Executive Blvd., Bethesda, MD 20852, USA. jiale@mail.nih.gov
18. A Phase 1 and pharmacokinetic clinical trial of paclitaxel for the treatment of refractory leukemia in children: a Children's Oncology Group study. Year Published: 2008
Texas Children's Cancer Center/Baylor College of Medicine, Houston, Texas, USA. tmhorton@txccc.org